Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab vs zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates
2012-001821-28Phase 4Completed
- Sponsor
- Amgen
- Start
- Sep 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of denosumab in osteoporosis (2 arms), sponsored by Amgen. Primary endpoints: Primary efficacy endpoint and Primary safety endpoint. Started Sep 2012; status: completed.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2012-001821-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001821-28.